By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Warner Chilcott Laboratories Ireland Ltd. et al. v. Impax Laboratories, Inc.
2:09-cv-01233; filed March 18, 2009 in the District Court of New Jersey
Infringement of U.S. Patent No. 6,958,161 ("Modified Release Coated Drug Preparation," issued October 25, 2005) following a Paragraph IV certification as part of Impax's filing of an ANDA to manufacture a generic version of Warner Chilcott's Doryx® (modified release doxycycline hyclate, used for adjunctive treatment of severe acne). View the complaint here.
Allergan Inc et al. v. Athena Cosmetics Inc et al.
8:09-cv-00328; filed March 16, 2009 in the Central District of California
Infringement of U.S. Patent Nos. 6,262,105 ("Method of Enhancing Hair Growth," issued July 17, 2001), 7,351,404 (same title, issued April 1, 2008), and 7,388,029 ("Compositions and Methods for Treating Hair Loss Using Non-Naturally Occurring Prostaglandins," issued June 17, 2008) based on defendants manufacture and sale of hair and/or eyelash growth products with prostamides. View the complaint here.
Stiefel Laboratories Inc. et al. v. Cobrek Pharmaceuticals Inc. et al.
1:09-cv-00167; filed March 13, 2009 in the District Court of Delaware
Infringement of U.S. Patent Nos. 7,141,237 ("Pharmaceutical Foam," issued November 28, 2006) and 7,374,747 (same title, issued May 20, 2008) following a Paragraph IV certification as part of Cobrek's filing of an ANDA to manufacture a generic version of Stiefel's Evoclin® (clindamycin phosphate foam, used to treat acne). View the complaint here.
Abbott Laboratories v. Matrix Laboratories Inc. et al.
1:09-cv-00174; filed March 13, 2009 in the District Court of Delaware
Abbott Laboratories v. Matrix Laboratories, Inc. et al.
1:09-cv-01586; filed March 13, 2009 in the Northern District of Illinois
The complaints in these cares are substantially identical. Infringement of U.S. Patent Nos. 7,148,359 ("Polymorph of a Pharmaceutical," issued December 12, 2006) and 7,364,752 ("Solid Dispersion Pharamaceutical Formulations," issued April 29, 2008) following a Paragraph IV certification as part of Matrix's filing of an ANDA to manufacture a generic version of Abbott's Kaletra® (lopinavir and ritonavir, used to treat HIV infections). View the Delaware complaint here.
Genzyme Corp. v. Impax Laboratories, Inc.
1:09-cv-00653; filed March 13, 2009 in the District Court of Maryland
Infringement of U.S. Patent No. 5,667,775 ("Phosphate-Binding Polymers for Oral Administration," issued on September 16, 1997) following a Paragraph IV certification as part of Impax's filing of an ANDA to manufacture a generic version of Genzyme's Renagel® (sevelamer hydrochloride, used for the control of serum phosphorus in patients with chronic kidney disease on dialysis). View the complaint here.
Wyeth v. Intervet Inc. et al.
1:09-cv-00161; filed March 12, 2009 in the District Court of Delaware
Infringement of U.S. Patent Nos. 6,703,023 ("Circovirus Sequences Associated with Piglet Weight Loss Disease," issued March 9, 2004), 7,223,407 (same title, issued May 29, 2007), 7,223,594 (same title, issued May 29, 2007), and 7,407,803 (same title, issued August 5, 2008) based on defendants' manufacture and sale of their Circumvent® PCV, Porcilis® PCV, and CircoFLEX® vaccines (porcine circovirus vaccines). View the complaint here.
Comments